Vasomotor Symptoms: Viewpoint from the Indian Subcontinent and Management of a Common Menopausal Problem

ABSTRACT

Vasomotor symptoms (VMS) are recognized to adversely affect the quality of life. The prevalence and the magnitude of VMS may vary across populations. Although a natural regression of VMS may be expected over a period of time, it remains the most common of symptoms for which women seek help. Menopausal hormone therapy (MHT) is currently the only treatment approved by the Food and Drug Administration that has shown uniform benefit in the management of VMS. In clinical situations when estrogen is or may be contraindicated, a finite number of alternative options, including use of neuroactive agents (SSRIs, SSNRs, and gabapentin), lifestyle changes, and nonprescription remedies such as phytoestrogens and black cohosh have been shown to provide relief, albeit with mixed results and questionable safety. Existing data identify an ethnic variation in the degree and frequency of VMS of aging; in this latter context, the Asian woman's perspective is dominantly conveyed from the perspective of Chinese and Japanese ethnicities, whereas data regarding the magnitude of burden of VMS in the postmenopausal women from other Asian ethnicities and races are sparse. This article reviews the symptoms and relates that VMS are of significant concern for the aging Asian women.

KEYWORDS

Hot flash - vasomotor symptoms - menopause - hormone therapy - phytoestrogens,

REFERENCES

• 1 Freedman R R. Pathophysiology and treatment of menopausal hot flashes.  Semin Reprod Med. 2005;  23(2) 117-125
• 2 Whiteman M K, Staropoli C A, Langenberg P W, McCarter R J, Kjerulff K H, Flaws J A. Smoking, body mass, and hot flashes in midlife women.  Obstet Gynecol. 2003;  101(2) 264-272
• 3 Gold E B, Sternfeld B, Kelsey J L et al. Relation of demographic and lifestyle factors to symptoms in a multi-racial/ethnic population of women 40-55 years of age.  Am J Epidemiol. 2000;  152(5) 463-473
• 4 Ivarsson T, Spetz A C, Hammar M. Physical exercise and vasomotor symptoms in postmenopausal women.  Maturitas. 1998;  29(2) 139-146
• 5 Chakravarti S, Collins W P, Newton J R, Oram D H, Studd J W. Endocrine changes and symptomatology after oophorectomy in premenopausal women.  Br J Obstet Gynaecol. 1977;  84(10) 769-775
• 6 Couzi R J, Helzlsouer K J, Fetting J H. Prevalence of menopausal symptoms among women with a history of breast cancer and attitudes toward estrogen replacement therapy.  J Clin Oncol. 1995;  13(11) 2737-2744
• 7 Biglia N, Cozzarella M, Cacciari F et al. Menopause after breast cancer: a survey on breast cancer survivors.  Maturitas. 2003;  45(1) 29-38
• 8 Gold E B, Colvin A, Avis N et al. Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: Study of Women's Health across the Nation.  Am J Public Health. 2006;  96(7) 1226-1235
• 9 Gold E B, Block G, Crawford S et al. Lifestyle and demographic factors in relation to vasomotor symptoms: baseline results from the Study of Women's Health across the Nation.  Am J Epidemiol. 2004;  159(12) 1189-1199
• 10 Shah D, Agrawal S. A double-blind, randomized, placebo controlled trial to evaluate the efficacy of a phytoestrogen formulation on Indian women with menopausal symptoms.  Bombay Hosp J. 2006;  48(3) 449-454
• 11 Syed Alwi S A, Lee P Y, Awi I, Mallik P S, Md Haizal M N. The menopausal experience among indigenous women of Sarawak, Malaysia.  Climacteric. 2009;  12(6) 548-556
• 12 Limpaphayom K K, Darmasetiawan M S, Hussain R I, Burriss S W, Holinka C F, Ausmanas M K. Differential prevalence of quality-of-life categories (domains) in Asian women and changes after therapy with three doses of conjugated estrogens/medroxyprogesterone acetate: the Pan-Asia Menopause (PAM) study.  Climacteric. 2006;  9(3) 204-214
• 13 Maclennan A H, Broadbent J L, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes.  Cochrane Database Syst Rev. 2004;  4 CD002978
• 14 American College of Obstetricians and Gynecologists Women's Health Care Physicians . Executive summary. Hormone therapy.  Obstet Gynecol. 2004;  104(4, Suppl) 1S-4S
• 15 Utian W H, Archer D F, Bachmann G A North American Menopause Society et al. Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society.  Menopause. 2008;  15(4 Pt 1) 584-602
• 16 Utian W H, Shoupe D, Bachmann G, Pinkerton J V, Pickar J H. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate.  Fertil Steril. 2001;  75(6) 1065-1079
• 17 Ettinger B. Vasomotor symptom relief versus unwanted effects: role of estrogen dosage.  Am J Med. 2005;  118(Suppl 12B) 74-78
• 18 Pasqualini J R. Progestins and breast cancer.  Gynecol Endocrinol. 2007;  23(Suppl 1) 32-41
• 19 Stovall D W, Pinkerton J V. Estrogen agonists/antagonists in combination with estrogen for prevention and treatment of menopause-associated signs and symptoms.  Womens Health (Lond Engl). 2008;  4(3) 257-268
• 20 Grady D, Ettinger B, Tosteson A N, Pressman A, Macer J L. Predictors of difficulty when discontinuing postmenopausal hormone therapy.  Obstet Gynecol. 2003;  102(6) 1233-1239
• 21 Sestak I, Kealy R, Edwards R, Forbes J, Cuzick J. Influence of hormone replacement therapy on tamoxifen-induced vasomotor symptoms.  J Clin Oncol. 2006;  24(24) 3991-3996
• 22 Stovall D W, Utian W H, Gass M L et al. The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety.  Menopause. 2007;  14(3 Pt 1) 510-517
• 23 Pinkerton J V, Shifren J L, La Valleur J, Rosen A, Roesinger M, Siddhanti S. Influence of raloxifene on the efficacy of an estradiol-releasing ring for treating vaginal atrophy in postmenopausal women.  Menopause. 2003;  10(1) 45-52
• 24 Valiati B, Capp E, Edelweiss M I, de Freitas F M, Wender M C. Effect of raloxifene and low-dose percutaneous 17β-estradiol on menopause symptoms and endometrium—a randomized controlled trial.  Maturitas. 2009;  62(1) 81-84
• 25 Lewiecki E M. Bazedoxifene and bazedoxifene combined with conjugated estrogens for the management of postmenopausal osteoporosis.  Expert Opin Investig Drugs. 2007;  16(10) 1663-1672
• 26 Komm B S, Kharode Y P, Bodine P V, Harris H A, Miller C P, Lyttle C R. Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity.  Endocrinology. 2005;  146(9) 3999-4008
• 27 Miller P D, Chines A A, Christiansen C et al.. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study.  J Bone Miner Res. 2008;  23(4) 525-535
• 28 Pinkerton J V, Utian W H, Constantine G D, Olivier S, Pickar J H. Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial.  Menopause. 2009;  16(6) 1116-1124
• 29 Stovall D W, Pinkerton J V. MF-101, an estrogen receptor β agonist for the treatment of vasomotor symptoms in peri- and postmenopausal women.  Curr Opin Investig Drugs. 2009;  10(4) 365-371
• 30 Loprinzi C L, Sloan J, Stearns V et al. Newer antidepressants and gabapentin for hot flashes: an individual patient pooled analysis.  J Clin Oncol. 2009;  27(17) 2831-2837
• 31 Casper R F. Is paroxetine an effective treatment for hot flashes?.  Nat Clin Pract Endocrinol Metab. 2006;  2(5) 250-251
• 32 Pandya K J, Raubertas R F, Flynn P J et al. Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center Community Clinical Oncology Program study.  Ann Intern Med. 2000;  132(10) 788-793
• 33 Goldberg R M, Loprinzi C L, O'Fallon J R et al. Transdermal clonidine for ameliorating tamoxifen-induced hot flashes.  J Clin Oncol. 1994;  12(1) 155-158
• 34 Laufer L R, Erlik Y, Meldrum D R, Judd H L. Effect of clonidine on hot flashes in postmenopausal women.  Obstet Gynecol. 1982;  60(5) 583-586
• 35 Guttuso Jr T, Kurlan R, McDermott M P, Kieburtz K. Gabapentin's effects on hot flashes in postmenopausal women: a randomized controlled trial.  Obstet Gynecol. 2003;  101(2) 337-345
• 36 Pandya K J, Morrow G R, Roscoe J A et al. Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial.  Lancet. 2005;  366(9488) 818-824
• 37 North American Menopause Society . Treatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society.  Menopause. 2004;  11(1) 11-33
• 38 Kuiper G G, Carlsson B, Grandien K et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta.  Endocrinology. 1997;  138(3) 863-870
• 39 Nagata C, Shimizu H, Takami R, Hayashi M, Takeda N, Yasuda K. Hot flushes and other menopausal symptoms in relation to soy product intake in Japanese women.  Climacteric. 1999;  2(1) 6-12
• 40 Van Patten C L, Olivotto I A, Chambers G K et al. Effect of soy phytoestrogens on hot flashes in postmenopausal women with breast cancer: a randomized, controlled clinical trial.  J Clin Oncol. 2002;  20(6) 1449-1455
• 41 Upmalis D H, Lobo R, Bradley L, Warren M, Cone F L, Lamia C A. Vasomotor symptom relief by soy isoflavone extract tablets in postmenopausal women: a multicenter, double-blind, randomized, placebo-controlled study [published correction appears in Menopause 2000;7:422].  Menopause. 2000;  7(4) 236-242
• 42 Quella S K, Loprinzi C L, Barton D L et al. Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: A North Central Cancer Treatment Group Trial.  J Clin Oncol. 2000;  18(5) 1068-1074
• 43 Albertazzi P, Pansini F, Bonaccorsi G, Zanotti L, Forini E, De Aloysio D. The effect of dietary soy supplementation on hot flushes [published correction appears in Obstet Gynecol 2001;98:702].  Obstet Gynecol. 1998;  91(1) 6-11
• 44 Han K K, Soares Jr J M, Haidar M A, de Lima G R, Baracat E C. Benefits of soy isoflavone therapeutic regimen on menopausal symptoms.  Obstet Gynecol. 2002;  99(3) 389-394
• 45 Krebs E E, Ensrud K E, MacDonald R, Wilt T J. Phytoestrogens for treatment of menopausal symptoms: a systematic review.  Obstet Gynecol. 2004;  104(4) 824-836
• 46 Lethaby A E, Brown J, Marjoribanks J, Kronenberg F, Roberts H, Eden J. Phytoestrogens for vasomotor menopausal symptoms.  Cochrane Database Syst Rev. 2007;  4(4) CD001395
• 47 Low Dog T, Powell K L, Weisman S M. Critical evaluation of the safety of Cimicifuga racemosa in menopause symptom relief.  Menopause. 2003;  10(4) 299-313
• 48 Mahady G B. Is black cohosh estrogenic?.  Nutr Rev. 2003;  61(5 Pt 1) 183-186
• 49 Mahady G B. Black cohosh (Actaea/Cimicifuga racemosa): review of the clinical data for safety and efficacy in menopausal symptoms.  Treat Endocrinol. 2005;  4(3) 177-184
• 50 Huntley A, Ernst E. A systematic review of the safety of black cohosh.  Menopause. 2003;  10(1) 58-64
• 51 Borrelli F, Ernst E. Black cohosh (Cimicifuga racemosa): a systematic review of adverse events.  Am J Obstet Gynecol. 2008;  199(5) 455-466
• 52 Joy D, Joy J, Duane P. Black cohosh: a cause of abnormal postmenopausal liver function tests.  Climacteric. 2008;  11(1) 84-88
• 53 Hirata J D, Swiersz L M, Zell B, Small R, Ettinger B. Does dong quai have estrogenic effects in postmenopausal women? A double-blind, placebo-controlled trial.  Fertil Steril. 1997;  68(6) 981-986
• 54 Chenoy R, Hussain S, Tayob Y, O'Brien P M, Moss M Y, Morse P F. Effect of oral gamolenic acid from evening primrose oil on menopausal flushing.  BMJ. 1994;  308(6927) 501-503
• 55 Wiklund I K, Mattsson L A, Lindgren R, Limoni C. Swedish Alternative Medicine Group . Effects of a standardized ginseng extract on quality of life and physiological parameters in symptomatic postmenopausal women: a double-blind, placebo-controlled trial.  Int J Clin Pharmacol Res. 1999;  19(3) 89-99
• 56 Coon J T, Ernst E. Panax ginseng: a systematic review of adverse effects and drug interactions.  Drug Saf. 2002;  25(5) 323-344
• 57 Pittler M H, Ernst E. Efficacy of kava extract for treating anxiety: systematic review and meta-analysis.  J Clin Psychopharmacol. 2000;  20(1) 84-89